Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2025 Jan-Dec;67(1):e70104.
doi: 10.1111/ped.70104.

A phase I/IIa trial of atorvastatin in Japanese patients with acute Kawasaki disease and coronary artery aneurysms

Kenji Furuno  1 , Eisuke Suganuma  2 , Hiroshi Masuda  3 , Zenpei Kano  4 , Jumpei Saito  5 , Kensuke Shoji  6 , Ken-Ichi Imadome  7 , Shoko Imai  8 , Shinobu Kobayashi  9 , Chisato Shimizu  10 , Adriana H Tremoulet  10 , Jane C Burns  10 , Tohru Kobayashi  11   12
Affiliations
Clinical Trial

A phase I/IIa trial of atorvastatin in Japanese patients with acute Kawasaki disease and coronary artery aneurysms

Kenji Furuno et al. Pediatr Int. 2025 Jan-Dec.

Abstract

Background: In the United States, a phase I/IIa dose-escalation study of atorvastatin in Kawasaki disease (KD) patients with coronary artery aneurysms (CAAs) demonstrated the safety and pharmacokinetics (PK) of atorvastatin. However, the tolerability and PK of atorvastatin in Japanese KD patients with CAAs remain unknown.

Methods: This multicenter, single-arm, open-label, phase I/IIa study of atorvastatin in acute KD patients with CAAs in Japan recruited patients for a 3 + 3 dose-escalation study of a 6-week course of atorvastatin (0.125-0.5 mg/kg/day). The primary outcome was the safety of atorvastatin. The secondary outcomes were the PK of atorvastatin, biomarkers of inflammation, and echocardiographic assessment of CAAs.

Results: We enrolled nine KD patients in this study. No dose-limiting toxicity was observed. Therefore, we determined the maximum tolerated dose was 0.5 mg/kg/day. Although there were no serious adverse drug reactions, two participants showed minor elevations in aspartate or alanine aminotransferase that recovered spontaneously without discontinuation of atorvastatin. The Z-scores of each coronary artery decreased from baseline to the 6-week visit except for one lesion. The serum concentration of atorvastatin was similar to those reported in PK studies of atorvastatin conducted in children with KD in the United States between the ages of 2 and 17 years. No significant differences in estimated PK parameters were observed in each dose group compared to previous studies.

Conclusions: We found that atorvastatin was safe and a dose up to 0.5 mg/kg/day for 6 weeks was well-tolerated in Japanese children with acute KD and CAAs.

Keywords: Kawasaki disease; atorvastatin; coronary artery aneurysm; pharmacokinetics; safety.

PubMed Disclaimer

References

REFERENCES

    1. Burns JC, Glodé MP. Kawasaki syndrome. Lancet. 2004;364(9433):533–544.
    1. Newburger JW, Takahashi M, Beiser AS, Burns JC, Bastian J, Chung KJ, et al. A single intravenous infusion of gamma globulin as compared with four infusions in the treatment of acute Kawasaki syndrome. N Engl J Med. 1991;324:1633–1639.
    1. Kobayashi T, Saji T, Otani T, Takeuchi K, Nakamura T, Arakawa H, et al. Efficacy of immunoglobulin plus prednisolone for prevention of coronary artery abnormalities in severe Kawasaki disease (RAISE study): a randomised, open‐label, blinded‐endpoints trial. Lancet. 2012;379:1613–1620.
    1. Ae R, Makino N, Kuwabara M, Matsubara Y, Kosami K, Sasahara T, et al. Incidence of Kawasaki disease before and after the COVID‐19 pandemic in Japan: results of the 26th Nationwide survey, 2019 to 2020. JAMA Pediatr. 2022;176:1217–1224.
    1. Schmidt‐Lucke C, Fichtlscherer S, Rössig L, Kämper U, Dimmeler S. Improvement of endothelial damage and regeneration indexes in patients with coronary artery disease after 4 weeks of statin therapy. Atherosclerosis. 2010;211:249–254.

Publication types

Substances

LinkOut - more resources